MVP与HVP方案治疗晚期NSCLC前瞻随机研究

A Prospective Randomized Sdudy Comparing MVP and MVP Regimens in the Treatment of Advanced Non-small Cell Lung Cancer

摘要: 目的　比较MVP(MMC +VDS +DDP)与HVP(HCPT +VDS +DDP)方案治疗晚期非小细胞肺癌 (NSCLC)的近期、远期疗效和不良反应。方法　将 88例NSCLC随机分为MVP组和HVP组, 分别给予MVP和HVP方案化疗 3～ 5周期, 按WHO标准评定疗效和不良反应。结果　两组有效率 (CR +PR)分别为 36 %和 2 6 %, 二组间疗效差异无显著性意义 (P >0 .0 5 )。二组中位缓解期、中位生存期、1年生存率和 2年生存率相似。二组主要毒副反应有骨髓抑制和消化道反应, 二组毒副反应相似。结论　MVP方案疗效稍高于HVP方案, 所以化疗时宜选MVP方案

Abstract: Objective To evaluate the recent and long response and toxicity of MVP and HVP regimens in the treatment of advanced NSCLC. Methods A total of 88 cases with advanced NSCLC was randomized into two groups: MVP group (MMC+VDS+DDP), HVP group (HCPT+VDS+DDP). All patients received 3～5 cycles of chemotherapy except 4 patients. Results The response rate was 36%(15/42) in the MVP and 26%(11/42) in the HVP, no significant difference was detected between the groups (P>0.05). No significant difference was detec...